Institutional cost savings through dose banding strategy of Pembrolizumab in oncology patients: a real-world data analysis. Universitas Scientiarum, [S. l.], p. S19, 2025. DOI: 10.11144/Javeriana.SCSI30.icst. Disponível em: https://revistas.javeriana.edu.co/index.php/scientarium/article/view/41540. Acesso em: 10 nov. 2025.